ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Thursday, 12 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results · Q4 FY26

Parmax Pharma Q4 FY26 Results: Net Loss of ₹0.6 Cr, Loss Narrows

Parmax Pharma Ltd reported revenue from operations of ₹3.3 Cr (-31.2% YoY) and a net loss of ₹0.6 Cr for Q4 FY26.

Q4 FY26 at a glance · ₹ crore
MetricQ4 FY26Q3 FY26Q4 FY25
Revenue from operations3.34.34.8
Other income0.00.0-0.1
Total income3.34.34.7
Profit before exceptional items & tax-2.3-0.7-0.7
Exceptional items0.00.01.1
Profit before tax-2.3-0.7-1.8
Net profit-0.6-0.7-1.5
Operating margin-69.7%-16.3%-38.3%

A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.

Growth
Revenue, year on year-31.20%
Source

BSE results filing, NSE: PARMAX. Figures extracted from the filing.

Read the filing ↗

Parmax Pharma Ltd: key numbers

Share price
₹135.00
Market cap
₹50.51 Cr
Revenue (annual)
₹12.11 Cr
Net profit (annual)
₹-4.16 Cr
P/E (TTM)
-42.3×Sector 43.8×
Promoter holding
64.66%+33.86% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Parmax Pharma Ltd

All →